Results 91 to 100 of about 4,256 (179)

Glycemic and Renal Effects of SGLT2 Inhibitors in Monogenic Diabetes: A Real‐World National Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9633-9643, October 2026.
ABSTRACT Aims Evidence regarding the efficacy and safety of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in monogenic diabetes is limited. We evaluated real‐world metabolic, renal, and safety outcomes of SGLT2i therapy in adults with monogenic diabetes.
Estelle Audrain, Pierre Bel Lassen, Christine Bellanné‐Chantelot, Marie Christine Vantyghem, Hippolyte Dupuis, Tiphaine Vidal‐Trecan, Nicolas Chevalier, Danièle Dubois‐Laforgue, Sophie Lamothe, Camille Vatier, Orianne Villard, René Valéro, Claire Briet, Corinne Vigouroux, Cécile Ciangura, Chloé Amouyal   +15 more
wiley   +1 more source

SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular–Kidney–Metabolic Syndrome

Biomedicines
Cardiovascular–Kidney–Metabolic (CKM) syndrome symbolizes a single pathophysiologic entity including obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease.
Aryan Gajjar, Arvind Kumar Raju, Amani Gajjar, Mythili Menon, Syed Asfand Yar Shah, Sourbha Dani, Andrew Weinberg   +6 more
doaj   +1 more source

Diabetes Treatment with Dapagliflozin and Its Combinations: Insights from Clinical Practice

Journal of Diabetology
Objective: To evaluate the perception of clinicians about the association of heart failure (HF) and type 2 diabetes mellitus (T2DM) and the utilization of dapagliflozin-based combination therapies for cardiorenal protection in Indian patients with T2DM ...
Akshay Bafna, Ajit Mehta, Rajeev Garg, Jayagopal Pathiyil Balagopalan, Rajesh Rajput, Nitin Zalte, Preethi Naik, Amarnath Sugumaran, Senthilnathan Mohanasundaram   +8 more
doaj   +1 more source

SGLT2 Inhibitors: Multifaceted Therapeutic Agents in Cardiometabolic and Renal Diseases

Metabolites
Background: Sodium–glucose cotransporter-2 inhibitors (SGLT2is), initially developed as antihyperglycemic agents, have emerged as multifunctional therapeutics with profound cardiorenal and metabolic benefits.
Ana Checa-Ros, Owahabanun-Joshua Okojie, Luis D’Marco   +2 more
doaj   +1 more source

Time to Insulin Initiation Among Patients With Type 2 Diabetes Treated With Second‐Line Antidiabetic Drugs

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9655-9667, October 2026.
ABSTRACT Objective To examine the effect of second‐line treatments (insulin secretagogues, thiazolidinediones, glucagon‐like peptide‐1 (GLP‐1) receptor agonists, dipeptidyl peptidase‐4 (DPP‐4) inhibitors or sodium‐glucose co‐transporter 2 (SGLT‐2) inhibitors) on time to insulin initiation among patients with type 2 diabetes.
Ya‐Hui Yu, Qi Zhang, Estefania Zapata‐Bravo, Robert W. Platt, Pauline Reynier, Oriana H. Y. Yu, Kristian B. Filion   +6 more
wiley   +1 more source

Alpha Tocopherol Outperforms Melatonin and Silymarin Antioxidant Defense Against Cyclophosphamide Induced Cardiorenal Toxicity

Proceedings
Introduction: Cyclophosphamide induces cardio-renal oxidative stress by its metabolite, acrolein. Alpha tocopherol, silymarin and melatonin are predetermined antioxidants, but comparative data on their capability to conserve tissue integrity is limited.
Maryam Saqib, Noaman Ishaq, Zari Salahuddin, Maryam Nadeem, Sarha, Iqra Ijaz   +5 more
doaj   +2 more sources

The Putative Role of the Antiageing Protein Klotho in Cardiovascular and Renal Disease

International Journal of Hypertension, 2012
Ageing is a multifactorial process often characterized by a progressive decline in physiological function(s). Ageing can and is often associated with an increased incidence of cardiovascular and renal disease.
Giuseppe Maltese, Janaka Karalliedde
doaj   +1 more source

Progress in Synthesis and Pharmacology of Telmisartan

Chemistry &Biodiversity, Volume 23, Issue 9, September 2026.
Telmisartan is a benzimidazole derivative and a well‐known drug to treat hypertension. This review provides synthesis and understanding of telmisartan as an antihypertensive drug through two mechanisms of actions: RAAS inhibitor and PPARγ receptor. Effective repurposing of this drug for various diseases like chronic kidney illness, diabetes, fatty ...
Megha, Richa Srivastava, Ram Singh
wiley   +1 more source

Cardiorenal protective effects of dapagliflozin combined with valsartan in patients with type 2 diabetes mellitus and hypertension: a retrospective cohort study

Frontiers in Endocrinology
BackgroundHypertension and Type 2 Diabetes Mellitus (T2DM) interact to increase cardiorenal risk. This study evaluated the cardiorenal efficacy of dapagliflozin combined with valsartan in patients with coexisting T2DM and hypertension.MethodsThis ...
Zhengrong Zhou, Kaizheng Gong
doaj   +1 more source

Lower AKI Risk and Higher Survival With Microaxial Flow Pump Support During Elective PCI: A Propensity Score‐Matched Study

Catheterization and Cardiovascular Interventions, Volume 108, Issue 3, Page 935-945, September 1, 2026.
ABSTRACT Background Acute kidney injury (AKI) is associated with worse outcomes after percutaneous coronary intervention (PCI). Previous, smaller studies suggested nephroprotective effects of micro‐axial flow pump (mAFP) during PCI. This study aimed to compare renal outcomes of high‐risk PCI with mAFP or intraaortic balloon pump (IABP) support.
Elric Zweck, Andrew Shaw, Amin Polzin, Nudrat Noor, Sathya Unudurthi, Michael Cuchiara, Kai M. Schmidt‐Ott, Malte Kelm, Ralf Westenfeld, Rafael Kramann, Ravindra L. Mehta   +10 more
wiley   +1 more source